Profile data is unavailable for this security.
About the company
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
- Revenue in USD (TTM)40.33bn
- Net income in USD5.63bn
- Incorporated1900
- Employees114.00k
- LocationAbbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com
More ▼
Mergers & acquisitions
| Acquired company | ABT:NYQ since announced | Transaction value |
|---|---|---|
| Bigfoot Biomedical Inc | 4.31% | -- |
Data delayed at least 15 minutes, as of Apr 19 2024 21:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc | 19.55bn | 1.39bn | 38.77bn | 51.00k | 27.99 | 5.42 | 18.96 | 1.98 | 3.04 | 3.03 | 42.77 | 15.67 | 0.6518 | 5.65 | 4.44 | 383,372.60 | 5.39 | -- | 7.45 | -- | 40.52 | -- | 8.28 | -- | 0.8295 | 5.43 | 0.5636 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| DexCom Inc | 3.62bn | 541.50m | 51.77bn | 9.60k | 104.76 | 25.02 | 71.17 | 14.29 | 1.28 | 1.28 | 8.55 | 5.37 | 0.6215 | 3.04 | 4.29 | 377,322.90 | 9.29 | 8.30 | 13.11 | 10.50 | 63.65 | 65.90 | 14.95 | 14.14 | 2.48 | -- | 0.5465 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Edwards Lifesciences Corp | 6.00bn | 1.40bn | 52.04bn | 19.80k | 37.56 | 7.81 | 33.70 | 8.67 | 2.30 | 2.30 | 9.85 | 11.06 | 0.6802 | 1.35 | 8.47 | 303,272.70 | 15.85 | 16.63 | 18.21 | 19.12 | 77.02 | 76.71 | 23.30 | 24.84 | 2.40 | -- | 0.0816 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Becton Dickinson and Co | 19.49bn | 1.27bn | 67.36bn | 73.00k | 53.21 | 2.66 | 18.99 | 3.46 | 4.38 | 4.23 | 67.25 | 87.68 | 0.3699 | 3.31 | 8.57 | 267,013.70 | 2.47 | 2.37 | 2.89 | 2.70 | 41.37 | 45.78 | 6.68 | 6.95 | 0.6435 | 6.45 | 0.3887 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
| Boston Scientific Corporation | 14.24bn | 1.57bn | 99.10bn | 48.00k | 62.95 | 5.12 | 35.83 | 6.96 | 1.07 | 1.07 | 9.73 | 13.16 | 0.4213 | 1.99 | 6.78 | 296,666.70 | 4.71 | 2.50 | 5.43 | 2.91 | 69.65 | 68.84 | 11.18 | 6.47 | 0.8170 | 5.16 | 0.3179 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Medtronic PLC | 32.32bn | 4.20bn | 105.15bn | 95.00k | 25.11 | 2.03 | 15.23 | 3.25 | 3.15 | 3.15 | 24.27 | 38.95 | 0.3495 | 2.00 | 5.45 | 340,210.50 | 4.58 | 4.78 | 5.28 | 5.37 | 65.73 | 67.68 | 13.10 | 14.28 | 1.71 | 30.78 | 0.3263 | 72.49 | -1.45 | 0.8366 | -25.42 | -6.95 | 6.44 | 8.13 |
| Stryker Corp | 20.50bn | 3.17bn | 124.58bn | 52.00k | 39.70 | 6.69 | 29.71 | 6.08 | 8.25 | 8.25 | 53.42 | 48.92 | 0.5338 | 1.67 | 5.59 | 394,192.30 | 8.24 | 6.60 | 10.12 | 7.84 | 63.90 | 63.99 | 15.44 | 13.13 | 0.9689 | -- | 0.4114 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Intuitive Surgical, Inc. | 7.12bn | 1.80bn | 132.08bn | 13.68k | 74.11 | 9.86 | 58.13 | 18.54 | 5.03 | 5.03 | 19.93 | 37.77 | 0.5014 | 2.27 | 6.88 | 520,919.90 | 12.79 | 12.42 | 14.44 | 13.83 | 66.39 | 67.60 | 25.51 | 26.31 | 4.02 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Abbott Laboratories | 40.33bn | 5.63bn | 182.66bn | 114.00k | 32.69 | -- | 21.39 | 4.53 | 3.22 | 3.22 | 23.06 | -- | -- | -- | -- | 353,736.80 | -- | 7.72 | -- | 9.39 | 55.22 | 56.73 | 13.96 | 14.39 | -- | 22.58 | -- | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Thermo Fisher Scientific Inc | 42.86bn | 6.00bn | 206.71bn | 122.00k | 35.05 | 4.48 | 21.94 | 4.82 | 15.45 | 15.45 | 110.46 | 120.87 | 0.4376 | 4.80 | 4.49 | 351,286.90 | 6.14 | 7.79 | 7.31 | 9.11 | 39.90 | 44.94 | 14.03 | 16.76 | 1.39 | 13.56 | 0.4271 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
Data as of Apr 19 2024. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD
33.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 149.15m | 8.60% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 86.59m | 4.99% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 86.30m | 4.97% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 74.69m | 4.30% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 64.29m | 3.71% |
| Geode Capital Management LLCas of 31 Dec 2023 | 32.85m | 1.89% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 32.24m | 1.86% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 20.21m | 1.17% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 19.22m | 1.11% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2023 | 16.15m | 0.93% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
